Comparative Pharmacology
Head-to-head clinical analysis: GLUCOPHAGE XR versus RIOMET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLUCOPHAGE XR versus RIOMET.
GLUCOPHAGE XR vs RIOMET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Biguanide; decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Biguanide that decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Metformin XR: initial 500 mg orally once daily with evening meal, increase by 500 mg weekly; max 2000 mg per day (as XR, given once or divided twice daily).
Oral, 500 mg twice daily or 850 mg once daily, increased gradually to 2000 mg daily in divided doses.
None Documented
None Documented
Terminal elimination half-life: 17.6 hours (range 9.1–40.6 hours); clinical context: reflects slow absorption from extended-release matrix; accumulation occurs with renal impairment
Terminal elimination half-life: 6.2 hours (range 4–12 hours); clinical context: 4–5 half-lives to steady state (approx 24–36 hours); prolonged in renal impairment (e.g., creatinine clearance <60 mL/min contraindicated)
Renal: 90% unchanged; fecal: minimal (<5%)
Renal (90% unchanged via glomerular filtration and tubular secretion); fecal (10%)
Category C
Category C
Biguanide Antidiabetic
Biguanide Antidiabetic